二苯甲酮-(O-乙基肟) | 58133-21-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 二苯甲酮-(O-乙基肟)
• 英文名称: benzophenon-(O-ethyl oxime )
• 英文别名: Benzophenon-(O-aethyl-oxim)；Benzophenon-O-ethyloxim；Benzophenone-O-ethyloxime；N-ethoxy-1,1-diphenylmethanimine
• CAS: 58133-21-4
• 化学式: C₁₅H₁₅NO
• 分子量: 225.29
• InChiKey: UKOFZMROMUQVBH-UHFFFAOYSA-N

物化性质

• 沸点：
  167 °C(Press: 11 Torr)
• 密度：
  0.99±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二苯甲酮-(O-乙基肟) 、 氰基硼氢化钠 以yielded 142 (0.17 g, 54% yield) as an oil的产率得到N-ethoxybenzhydrylamine
  参考文献：
  名称：

  GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING

  摘要：

  本发明一般涉及利用糖基转移酶可逆性合成核苷酸二磷酸（NDP）糖的材料和方法。本发明提供了改良反应可逆性并扩展糖供体特异性的工程糖基转移酶酶，与相应的非突变糖基转移酶酶相比，具有更好的反应可逆性和扩展的糖供体特异性。这些试剂提供了有利的NDP糖路线，用于随后在各种生物医学应用中使用，包括酶促和化学酶促糖随机化。

  公开号：

  US20130004979A1
• 作为产物：
  描述：

  二苯甲酮肟 、 碘乙烷 在 sodium ethanolate 作用下， 生成 二苯甲酮-(O-乙基肟)
  参考文献：
  名称：

  Spiegler, Chemische Berichte, 1884, vol. 17, p. 810

  摘要：

  DOI：

文献信息

• AMINOPYRIMIDINES AS KINASE MODULATORS
  申请人：Gaul David Michael

  公开号：US20070021435A1

  公开（公告）日：2007-01-25

  The invention is directed to aminopyrimidine compounds of Formula I: where R 3 , B, Z, r and R 1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的氨基嘧啶化合物：其中R3、B、Z、r和R1的定义如本文所述，所述化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，所述化合物的用途为在细胞或受体中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，并用于预防或治疗与FLT3和/或c-kit和/或TrkB相关的细胞增殖性疾病和/或疾病。本发明还涉及包含本发明化合物的药物组合物以及治疗癌症和其他细胞增殖性疾病的方法。
• Pornet,J.; Miginiac,L., Bulletin de la Societe Chimique de France, 1975, p. 1849 - 1854
  作者：Pornet,J.、Miginiac,L.

  DOI：——

  日期：——
• PORNET J.; MIGINIAC L., BULL. SOC. CHIM. FRANCE <BSCF-AS>, 1975, NO 7-8, PART. 2, 1849-1854
  作者：PORNET J.、 MIGINIAC L.

  DOI：——

  日期：——
• ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080125444A1

  公开（公告）日：2008-05-29

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• OXIMYL HCV SERINE PROTEASE INHIBITORS
  申请人：GAI YONGHUA

  公开号：US20090155210A1

  公开（公告）日：2009-06-18

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.